Myriad Genetics Inc (NASDAQ:MYGN) — Market Cap & Net Worth
Market Cap & Net Worth: Myriad Genetics Inc (MYGN)
Myriad Genetics Inc (NASDAQ:MYGN) has a market capitalization of $414.63 Million ($414.63 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #13360 globally and #3189 in its home market, demonstrating a 2.48% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Myriad Genetics Inc's stock price $4.54 by its total outstanding shares 94448210 (94.45 Million). Review Myriad Genetics Inc total liabilities to assess the company's total debt and financial obligations.
Myriad Genetics Inc Market Cap History: 2015 to 2026
Myriad Genetics Inc's market capitalization history from 2015 to 2026. Data shows change from $4.08 Billion to $428.79 Million (-18.46% CAGR).
Index Memberships
Myriad Genetics Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Dow Jones Biotechnology
DJUSBT
|
$1.07 Trillion | 0.04% | #25 of 39 |
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.02% | #353 of 976 |
|
NASDAQ Composite
IXIC
|
$41.03 Trillion | 0.00% | #1290 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.64 Trillion | 0.06% | #562 of 602 |
Weight: Myriad Genetics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Myriad Genetics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Myriad Genetics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.70x
Myriad Genetics Inc's market cap is 0.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.57 Billion | $753.80 Million | $125.30 Million | 2.09x | 12.57x |
| 2017 | $3.24 Billion | $771.40 Million | $21.80 Million | 4.21x | 148.80x |
| 2018 | $2.75 Billion | $772.60 Million | $131.00 Million | 3.55x | 20.96x |
| 2019 | $2.57 Billion | $851.10 Million | $4.60 Million | 3.02x | 559.09x |
| 2020 | $1.87 Billion | $557.00 Million | -$223.70 Million | 3.35x | N/A |
| 2021 | $2.61 Billion | $690.60 Million | -$27.20 Million | 3.77x | N/A |
| 2022 | $1.37 Billion | $678.40 Million | -$112.00 Million | 2.02x | N/A |
| 2023 | $1.81 Billion | $753.20 Million | -$263.30 Million | 2.40x | N/A |
| 2024 | $1.29 Billion | $837.60 Million | -$127.30 Million | 1.55x | N/A |
| 2025 | $580.86 Million | $824.50 Million | -$365.90 Million | 0.70x | N/A |
Competitor Companies of MYGN by Market Capitalization
Companies near Myriad Genetics Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Myriad Genetics Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #131 globally with a market cap of $174.56 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $125.14 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #621 globally with a market cap of $44.18 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #664 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #131 | Thermo Fisher Scientific Inc | NYSE:TMO | $174.56 Billion | $464.61 |
| #189 | Danaher Corporation | NYSE:DHR | $125.14 Billion | $177.17 |
| #621 | IDEXX Laboratories Inc | NASDAQ:IDXX | $44.18 Billion | $562.09 |
| #664 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Myriad Genetics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Myriad Genetics Inc's market cap moved from $4.08 Billion to $ 428.79 Million, with a yearly change of -18.46%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $428.79 Million | -26.18% |
| 2025 | $580.86 Million | -55.14% |
| 2024 | $1.29 Billion | -28.37% |
| 2023 | $1.81 Billion | +31.91% |
| 2022 | $1.37 Billion | -47.43% |
| 2021 | $2.61 Billion | +39.57% |
| 2020 | $1.87 Billion | -27.38% |
| 2019 | $2.57 Billion | -6.33% |
| 2018 | $2.75 Billion | -15.36% |
| 2017 | $3.24 Billion | +106.03% |
| 2016 | $1.57 Billion | -61.38% |
| 2015 | $4.08 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Myriad Genetics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $414.63 Million USD |
| MoneyControl | $414.63 Million USD |
| MarketWatch | $414.63 Million USD |
| marketcap.company | $414.63 Million USD |
| Reuters | $414.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Myriad Genetics Inc
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovar… Read more